Unfortunately, for we longs Dacogen loses its “protective” status this May.
While we will not feel an instant drop in revenues; never the less the market looks forward. Sadly we are not close to any new approved compound. Maybe someone out there knows a better date, but right now it looks at least 18 months out to even get a chance at one of the science projects proving out successfully!
Name the generic company? Why would you claim to be long, but think the share price is headed south. The market out there for dacogen is roughly $200M. I don't see a generic entering the picture. Just like vidaza. With the EU aml approval, we could be looking at $90M in revenues this year. But do some DD, show us a real concern. Until and unless you do research, you are as insignificant as loverboy.
I agree about the generics. Not too many companies go diving into the orphan drug markets, because the markets just aren't big enough. Generic Lipitor, yes. Generic Dacogen, maybe? Later? Perhaps if other indications get approved, but MDS market is too small.